Ovarian Cancer Research & News

The latest news about Ovarian Cancer

Watch here for posts about the latest ovarian cancer news.

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • August 15, 2014 5:16 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    New drug treatment beating ovarian cancer

    A new type of intensive chemotherapy is proving highly effective in treating women desperately ill with ovarian cancer, scientists announced today.

    The pioneering treatment is successful in 80% of patients whose first-line chemotherapy had failed, compared to rates of less than 15% under current therapies.

    The results, published in the British Journal of Cancer today, will provide fresh hope to the 7,000 women who are diagnosed with ovarian cancer each year in the UK. They have a survival rate of just 29% after five years.

    Currently, women whose tumours have returned have very limited options, with less than half responding to follow-up chemotherapy.

    The Dutch study involved 98 women with ovarian cancer whose first-line chemotherapy had initially been successful, but who had later relapsed.

    Researchers divided the women into three groups depending on the severity of their cancer and treated them with an intensive regime of cisplatin and another drug called etoposide. Read entire article >>


    Read more: http://www.dailymail.co.uk/health/article-96824/New-drug-treatment-beating-ovarian-cancer.html#ixzz3AVPrWkiw 

  • August 12, 2014 5:13 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Breakthroughs in ovarian cancer research

    Tuesday 12 August 2014 - 12am PST


    Scientists at A*STAR's Institute of Medical Biology (IMB) and the Bioinformatics Institute (BII) have found new clues to early detection and personalized treatment of ovarian cancer, currently one of the most difficult cancers to diagnose early due to the lack of symptoms that are unique to the illness.

    There are three predominant cancers that affect women - breast, ovarian and womb cancer. Of the three, ovarian cancer is of the greatest concern as it is usually diagnosed only at an advanced stage due to the absence of clear early warning symptoms. Successful treatment is difficult at this late stage, resulting in high mortality rates. Ovarian cancer has increased in prevalence in Singapore as well as other developed countries recently. It is now the fifth most common cancer in Singapore amongst women, with about 280 cases diagnosed annually and 90 deaths per year1 .

    Identifying Ovarian Cancer Earlier

    IMB scientists have successfully identified a biomarker of ovarian stem cells, which may allow for earlier detection of ovarian cancer and thus allow treatment at an early stage of the illness. Read entire article >>


  • July 16, 2014 5:22 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    HER3-positive circulating tumor cells home in on omentum; new target to thwart ovarian cancer spread

    Wednesday 16 July 2014 - 12am PST


    Circulating tumor cells spread ovarian cancer through the bloodstream, homing in on a sheath of abdominal fatty tissue where it can grow and metastasize to other organs, scientists at The University of Texas MD Anderson Cancer Center report in Cancer Cell.

    "This completely new way of thinking about ovarian cancer metastasis provides new potential avenues to predict and prevent recurrence or metastasis," said senior author Anil Sood, M.D., professor of Gynecologic Oncology and Reproductive Medicine and Cancer Biology.

    The researchers found the circulating tumor cells (CTCs) rely on HER3, a less-famous sibling of the HER2 receptor protein prominent in some breast cancers, to find their way to the omentum, a sheet of tissue that covers and supports abdominal organs. Read entire article >>


  • March 12, 2014 9:29 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Research for Her™, an Online Clinical Research Registry, Honored With Distinguished National Award

    Los Angeles - Jan. 14, 2014 – Research for Her™, a Cedars-Sinai online medical research database aimed at increasing women's participation in clinical studies, received the 2013 Award for Excellence from the Health Improvement Institute for its user-friendly electronic consent form.

    The Research for Her registry allows women to register for potential participation in clinical trials through an online, verified consent process that is just two pages long and written in nontechnical, easy-to-understand language. In comparison, a typical clinical trial consent form, even for low-risk clinical trials, is a printed document ranging from eight to 15 pages and includes complex medical and legal terminology . . .
    Read full article >>

  • March 10, 2014 11:34 AM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    PARP inhibitors in ovarian cancer:
    current status and future promise

    • Gynecologic Oncology Program, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston MA 02215

    Clinical investigation of poly(ADP-ribose) polymerase (PARP) inhibitors for ovarian cancer treatment has rapidly evolved from observations of single-agent in vitro activity of these agents in BRCA-deficient cancer cells in 2005 to the initiation of multiple phase III studies in 2013. With clinical trial design and treatment of ovarian cancer increasingly based on histological and molecular characteristics, PARP inhibitors are on the horizon of becoming the first biologic agents to be used to treat ovarian cancer based upon pre-selection characteristics of the patient’s cancer.
    Read more on ScienceDirect.com >>

  • February 19, 2014 12:05 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Contact: Garth Sundem
    University of Colorado Denver

    COXEN model picks the best drug for ovarian cancer

    There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched. Read entire article >>


  • December 04, 2013 1:30 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Canyon Ranch Center for Prevention and Health Promotion

    Canyon Ranch Center for Prevention
    and Health Promotion

    LIvES Study  - Lifestyle Intervention for oVarian cancer Enhanced Survival

    Download flyer PDF:  LIvES Study.pdf


    National Cancer Institute


    LIvES Study: Lifestyle Intervention for oVarian cancer Enhanced Survival The CRCPHP in partnership with the Arizona Cancer Center and the national Gynecological Oncology Group of the National Cancer Institute has launched the first comprehensive study to investigate the role of a healthy diet and physical activity behavioral intervention on ovarian cancer survival. One in 71 women will be diagnosed with ovarian cancer in their lifetime. Survival continues to be less than optimal and efforts to improve survival through healthy lifestyle have yet to be evaluated. This study will recruit over 1000 ovarian cancer survivors from across the country for a 2-year intervention. Study participants receive important health information to promote study engagement and healthy behavior change. The coaching is delivered via Internet using a new interactive coaching platform developed by the UA Arizona Research Laboratories at the BIO5 Institute. UA students from the College of Public Health and Nutritional Sciences undergo an extensive training program offered by center staff lead, Tracy Crane, a registered dietitian who coordinates this national study. With partnerships it is amazing what can be accomplished!

    See website >>

    Download flyer >> LIvES Study.pdf

  • June 13, 2013 12:00 PM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    Promising New Cancer Drugs Empower the Body’s Own Defense System

    The early success of a new class of cancer drugs, revealed in test results released here over the last several days, has raised hope among the world’s top cancer specialists that they may be on the verge of an important milestone in the fight against the disease.

    The excitement has spread to Wall Street. Shares of Merck and Bristol-Myers Squibb, which are developing such drugs, rose more than 3 percent on Monday after data from their studies was presented over the weekend at the meeting of the American Society of Clinical Oncology.

    The drugs, still generally in early testing, work in an entirely new way, by unleashing the immune system to attack cancer cells much as it attacks bacteria. That could be an alternative to often-debilitating chemotherapy.

    Read entire article >>
  • June 13, 2013 11:55 AM | Colorado Ovarian Cancer Alliance COCA (Administrator)

    ASCO: Targeted Rx Slows Ovarian Ca Progression

    CHICAGO -- Adding the oral anti-angiogenesis drug pazopanib (Votrient) to standard treatment extended disease-free survival in patients with advanced ovarian cancer by an average of 5.6 months, a phase III study showed.

    The time to progression was a median of 17.9 months among women taking pazopanib versus 12.3 months for those in the placebo arm (HR 0.77; 95% CI 0.64-0.91, P=0.0021), according to Andreas du Bois, MD, a professor of gynecologic oncology at Kliniken Essen Mitte in Essen, Germany, and colleagues

    "Our findings show that we finally have a drug that can maintain control over ovarian cancer growth achieved through initial treatments," du Bois said here at the American Society of Clinical Oncology meeting.

    Read entire article >>

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

COCA – Colorado Ovarian Cancer Alliance • copyright ©2005-2014
P.O. Box 9216, Denver, CO  80209 
Office as of Feb. 26, 2016 - 1777 S. Bellaire St., Suite 170, Denver, CO 80222
  direct 303.506.7014 ~ toll free 1.800.428.0642 ~ fax 1.866.517.0215  
Colorado Ovarian Cancer Alliance is a 501 (c)(3) organization

Powered by Wild Apricot Membership Software